How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder

and Assessment Methods ES-1 Evidence Summary Main Points • This update adds newly published studies on posttraumatic stress disorder (PTSD, 47 randomized controlled trials [RCTs]), studies targeting comorbid PTSD and substance use disorders (SUDs, 21 RCTs), and variables related to comorbidities such as SUDs and suicidal ideation/behavior, to the PTSD-Repository, a database of RCTs of interventions to treat PTSD. • We abstracted data from 389 RCTs, which included psychotherapeutic interventions (63 (...) /minimal attention, usual care, or placebo • Outcomes: o Overall PTSD outcome, PTSD diagnostic change o Other outcomes – Anxiety, anger, depression, functioning, quality of life, sleep, substance use, suicide- and self-directed violence-related outcomes including suicidal ideation/behavior, withdrawal due to adverse events, serious adverse events 3 • Timing: o No limitation on study duration or length of followup • Settings: o No limitation on study setting • Study Design: o Randomized controlled

2020 Effective Health Care Program (AHRQ)

42. Registries for Evaluating Patient Outcomes: A User's Guide: 4th Edition

attention on specific aspects of a particular disease that might otherwise be overlooked, or to provide data for clinicians to compare themselves with their peers. 7 For patients and patient advocacy organizations, a registry may increase understanding of the natural history of a disease, contribute to the development of treatment guidelines, or facilitate research on treatment. 8,9 From a payer’s perspective, registries can provide detailed information from large numbers of patients on how procedures

2020 Effective Health Care Program (AHRQ)

43. Management of Adult Overweight and Obesity

Concerns 121 Appendix J: Specific Behavioral Strategies Featured in Comprehensive Lifestyle Interventions 124 A. Goal Setting 124 B. Self-monitoring 124 C. Stimulus Control or Cue Reduction 124 D. Positive Reinforcement 124 E. Contingency Management 124 F. Stress Management 125 G. Problem-solving 125 H. Skill Training 125 I. Social Support 125 J. Cognitive Therapy 125 K. Relapse-prevention Training 125 Appendix K: Alternative Text Description of the Algorithm 127 Appendix L: Abbreviations 128 (...) and/or to establish a common understanding of how care will be coordinated and delivered. VA/DoD CPGs exist for Chronic Kidney Disease (CKD), b Diabetes Mellitus, c Hypertension, d and Chronic Insomnia Disorder/OSA. e See Standards of Care, Sidebar 1, and Sidebar 3 for guidance regarding the medical assessment of patients with overweight and obesity. I. Implementation This CPG is designed to be adapted by individual healthcare providers with consideration of local services, resources, and capacity (professional

2020 VA/DoD Clinical Practice Guidelines

44. Disorders of Ejaculation: An AUA/SMSNA Guideline

are not at all rare. The perception of rarity may stem from the frequency with which other disabling disorders of sexual function (primarily erectile dysfunction [ED]) are present in men with comorbid disruption of ejaculation. 3 The understanding of the neurophysiology of ejaculation and orgasm remains limited. Biomedical interventions for treatment of conditions that alter ejaculatory latency and control are scant. Although few such treatments have achieved regulatory approval, a number of interventions (...) Disorders of Ejaculation: An AUA/SMSNA Guideline Disorders of Ejaculation: An AUA/SMSNA Guideline - American Urological Association advertisement Toggle navigation About Us AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL

2020 American Urological Association

45. Interventions for Substance Use Disorders in Adolescents: A Systematic Review

Francisco San Francisco, CA vii Interventions for Substance Use Disorders in Adolescents: A Systematic Review Structured Abstract Objectives. This systematic review (SR) synthesizes the literature on behavioral, pharmacologic, and combined interventions for adolescents ages 12 to 20 years with problematic substance use or substance use disorder. We included interventions designed to achieve abstinence, reduce use quantity and frequency, improve functional outcomes, and reduce substance-related harms (...) ). Conclusions. Brief interventions: MI reduces heavy alcohol use (low SoE), alcohol use days (moderate SoE), and substance use–related problems (low SoE) but does not reduce cannabis use days (moderate SoE). Nonbrief interventions: Fam may be most effective in reducing alcohol use (low SoE). More research is needed to identify other effective intensive behavioral interventions for alcohol use disorder. Intensive interventions did not appear to decrease cannabis use (low SoE). Some interventions (CBT, CBT+MI

2020 Effective Health Care Program (AHRQ)

46. Treatment of Depression in Children and Adolescents

and harms of pharmacological and nonpharmacological treatments for child and adolescent depressive disorders. Key Messages • Cognitive behavioral therapy (CBT), fluoxetine, escitalopram, and combined fluoxetine plus CBT may reduce depressive symptoms in the short term; clinical significance is unclear. • CBT may improve symptoms and functional status. CBT plus medications may help prevent relapse. • Selective serotonin reuptake inhibitors (SSRIs) as a class may improve response and functional status (...) . • However, SSRIs may be associated with a higher risk of serious adverse events and with a higher risk of withdrawal. Paroxetine may be associated with a higher risk of suicidal ideation or behaviors. Evidence to judge the risk of suicidal ideation or behavior for SSRIs other than paroxetine is insufficient for major depressive disorder. However, this report excluded data on inpatients and those without depressive disorders whom the Food and Drug Administration included in finding an increased risk

2020 Effective Health Care Program (AHRQ)

47. Nonopioid Pharmacologic Treatments for Chronic Pain

events of interest were not reported (cognitive effects, misuse, addiction, substance use disorder).ES-9 Table C. Effects of antidepressants in placebo-controlled and head-to-head trials Condition Drug Pain Short Term Effect Size SOE Pain Intermediate Term Effect Size SOE Function Short Term Effect Size SOE Function Intermediate Term Effect Size SOE QoL Short Term Effect Size SOE QoL Intermediate Term Effect Size SOE Neuropathic pain Duloxetine vs. placebo Moderate ++ No evidence Small + No evidence (...) =019872. Accessed July 31, 2019. 11. Acetaminophen. https://www.drugs.com/monograph/acetami nophen.html. Accessed July 31, 2019. 12. Kansagara D, O'Neil M, Nugent S, et al. VA Evidence-based Synthesis Program Reports. Benefits and Harms of Cannabis in Chronic Pain or Post-traumatic Stress Disorder: A Systematic Review. Washington, DC: Department of Veterans Affairs (US); 2017. 13. Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis

2020 Effective Health Care Program (AHRQ)

48. Seasonal affective disorder

clinical management and monitoring are typically required. Light therapy and/or bupropion (extended release) may be used as prophylactic therapy. Definition All patients must meet the diagnostic criteria for recurrent major depression or bipolar mood disorder. Seasonal affective disorder (SAD) is then a sub-type specifier used to describe temporal variations of these disorders. As such, SAD is not considered a stand-alone diagnosis or comorbid condition to recurrent major depression or bipolar disorder (...) symptoms spring or summer depression manic/hypomanic symptoms somatic symptoms behavioural withdrawal functional impairments excessive alcohol use tachycardia increased systolic blood pressure restlessness exposure to diminished light during winter and increased light during summer residing at a northern latitude family history of SAD female gender age 20 to 30 years psychological factors (e.g., high neuroticism) psychiatric comorbidity (e.g., anxiety, ADHD, premenstrual dysphoric disorders) alcohol

2018 BMJ Best Practice

49. Guidance on the clinical management of anxiety disorders, specifically focusing on diagnosis and treatment strategies

capacity to think, plan and do complex tasks that also need attention in difficult situations. It is normal for a person’s current level of anxiety to affect their ability to perform. However, people with anxiety disorders experience very pronounced states of anxiety, often against a background of constant fear and worry. These severe states of anxiety can be disabling. Anxiety disorders involve unhelpful thinking patterns Having an anxiety disorder is not just a matter of being too anxious. People (...) covered in these guidelines is characterised by specific thoughts and behaviours: • • Panic disorder – sudden attacks of fear or anxiety (usually brief, but which may be so severe that the person thinks they might collapse or die), concern about the attacks recurring and avoidance of situa- tions in which they might recur. • • Social anxiety disorder (SAD) – fear and avoidance of situations where the person thinks they might be the centre of attention, concern about doing or saying something

2018 Royal Australian and New Zealand College of Psychiatrists

50. Buspirone

with buspirone versus atomoxetine monotherapy and placebo (...) in adult attention-deficit/hyperactivity disorder (ADHD). In this randomized, 8-week, 3-arm, double-blind, placebo-controlled trial conducted from November 2004 through December 2005, 241 adults with ADHD were randomly assigned in a 2:2:1 ratio to receive up to twice-daily atomoxetine and thrice-daily buspirone (n = 97), twice-daily atomoxetine (n = 97), or placebo (n = 47). Participants met the Diagnostic and Statistical Manual of Mental (...) Disorders, Fourth Edition, Text Revision criteria for ADHD. The 2012 10. Effects of Buspirone on Agitation Associated With Dementia. Ten patients with probable Alzheimer's disease participated in an open-label study of buspirone for agitation. The starting dose of 15 mg/day was increased by 5 mg every week until maximal improvement or 60 mg/day was reached. A significant decrease in agitation scores occurred at an average dose of 35 mg/day. Copyright © 1993 American Association for Geriatric Psychiatry

2018 Trip Latest and Greatest

51. Amphetamine

of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for amphetamine 1. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a childhood-onset disorder characterised by inattention, hyperactivity, and impulsivity. ADHD can persist into adulthood and can affects individuals' social and occupational functioning, as well as their quality of life and health. ADHD (...) hospitals forming two groups of participants. The patients reported amphetamine use at least once in the past month prior to the present study 2012 5. Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials Amphetamines and methylphenidate for paediatric ADHD Search National Elf Service Search National Elf Service » » » » Amphetamines and methylphenidate for paediatric ADHD: meta-analysis of n-of-1 trials May 24 2016 Posted by Attention-Deficit/Hyperactivity Disorder (ADHD

2018 Trip Latest and Greatest

52. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

in women) Autoimmune and other inflammatory disorders Major psychiatric disorders Treatment for infection with human immunodeficiency virus Atrial fibrillation LV hypertrophy CKD Obstructive sleep apnoea syndrome Social deprivation, the origin of many causes of CVD Obesity (measured by BMI) and central obesity (measured by waist circumference) Physical inactivity Psychosocial stress, including vital exhaustion Family history of premature CVD (occurring at age <55 years in men and <60 years in women (...) ) Autoimmune and other inflammatory disorders Major psychiatric disorders Treatment for infection with human immunodeficiency virus Atrial fibrillation LV hypertrophy CKD Obstructive sleep apnoea syndrome BMI = body mass index; CKD = chronic kidney disease; CVD = cardiovascular disease; LV = left ventricular. Table 6 Risk modifiers increasing cardiovascular risk estimated by the Systemic COronary Risk Evaluation (SCORE) system Social deprivation, the origin of many causes of CVD Obesity (measured by BMI

2018 European Society of Cardiology

53. Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder

.2012.07.008. PMID: 22921765. 32. Ivarsson D, Blom M, Hesser H, et al. Guided internet-delivered cognitive behavior therapy for post-traumatic stress disorder: a randomized controlled trial. Internet Interv. 2014 March;1(1):33-40. doi: 10.1016/j.invent.2014.03.002. 33. Kangas M, Milross C, Taylor A, et al. A pilot randomized controlled trial of a brief early intervention for reducing posttraumatic stress disorder, anxiety and depressive symptoms in newly diagnosed head and neck cancer patients (...) , Hertzberg MA, Moore SD, et al. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2007 Apr;27(2):193-7. doi: 10.1097/JCP.0b013e318032eaed. PMID: 17414245. 49. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000 Apr;283(14):1837-44. doi: 10.1001/jama.283.14.1837. PMID: 10770145. 50. Brady KT, Sonne SC, Anton RF, et al

2019 Effective Health Care Program (AHRQ)

54. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts

to Appendix A of the supplement. APA GUIDELINE FOR THE TREATMENT OF DEPRESSION ES-10 Table 1 Recommendations for the Child Population from the APA Guideline Development Panel for the Treatment of Depression 8 Recommendation Strength of Recommendation Justification Initial Treatment For initial treatment of child patients with depressive disorders 9 there was insufficient evidence to make a recommendation regarding any of the following psychotherapies/interventions 10 : • Behavioral therapy • Cognitive (...) therapy • Cognitive-behavioral therapy (CBT) • Family therapy • Play therapy • Problem-solving therapy • Psychodynamic therapy • Supportive therapy There was insufficient evidence to make a recommendation regarding pharmacotherapy for child patients with depressive disorders. Insufficient evidence for a recommendation Based on the literature reviewed that met the AMSTAR requirements, there was insufficient evidence to either recommend or not recommend use of the listed psychotherapies/interventions

2019 American Psychological Association

55. Heart Disease and Stroke Statistics Full Text available with Trip Pro

, Andrew Stokes , David L. Tirschwell , Connie W. Tsao , Mintu P. Turakhia , Lisa B. VanWagner , John T. Wilkins , Sally S. Wong , Salim S. Virani , Originally published 31 Jan 2019 Circulation. 2019;139:e56–e66 Each chapter listed in the Table of Contents (see next page) is a hyperlink to that chapter. The reader clicks the chapter name to access that chapter. Table of Contents Summary e57 1. About These Statistics e67 2. Cardiovascular Health e70 Health Behaviors 3. Smoking/Tobacco Use e87 4 (...) . Physical Inactivity e99 5. Nutrition e119 6. Overweight and Obesity e138 Health Factors and Other Risk Factors 7. High Blood Cholesterol and Other Lipids e161 8. High Blood Pressure e174 9. Diabetes Mellitus e193 10. Metabolic Syndrome e212 11. Kidney Disease e233 12. Sleep e249 Cardiovascular Conditions/Diseases 13. Total Cardiovascular Diseases e257 14. Stroke (Cerebrovascular Disease) e281 15. Congenital Cardiovascular Defects and Kawasaki Disease e327 16. Disorders of Heart Rhythm e346 17. Sudden

2019 American Heart Association

56. EANM Practice Guideline/SNMMI Procedure Standard for Dopaminergic Imaging in Parkinsonian Syndromes 1.0 Full Text available with Trip Pro

in the earliest stages of disease. 8. The presence of a dot shape with uptake reduction in both putamina has been repeatedly described in both patients with hemiparkinsonism and even in patients with premotor PD (i.e., in clinical trials carried out in patients with anosmia and/or REM sleep behavior disorders [ , , , ]. These findings testify to the high sensitivity of DAT SPECT in the earliest stages of disease and its high negative predictive value, which still remains one of its main strengths. 9. In IPD (...) . Introduction Parkinsonian syndromes are a group of diseases characterized by signs of parkinsonism, such as bradykinesia, rigidity, tremor, and postural instability. Idiopathic Parkinson’s disease (IPD) is the most common cause of parkinsonism, but several other etiologies result to the presence of parkinsonism. Indeed, parkinsonism can be present in all alpha synucleinopathies, which include Lewy body diseases (LBDs), a subset of disorders associated with the accumulation of Lewy bodies (LB) and neurites

2020 European Association of Nuclear Medicine

57. CPIC Guideline for Atomoxetine based on CYP2D6 genotype

is associated with clinical response to atomoxetine in attention- deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 34, 2135–2142 (2009). 3 2. T o d o r , I. et al. Evaluation of a potential metabolism- mediated drug- drug interaction between atomoxetine and bupropion in healthy volunteers. J. Pharm. Pharm. Sci. 19, 198–207 (2016). 33. Paulzen, M., Clement, H.W. & Grunder, G. Enhancement of ato- moxetine serum levels by co- administration of paroxetine. Int. J. Neuropsychopharmacol. 11, 289–291 (...) . Steven Leeder 7,8,* Atomoxetine is a nonstimulant medication used to treat attention- deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www. cpicpgx.org). The purpose of this guideline is to provide information

2019 Clinical Pharmacogenetics Implementation Consortium

59. Guidelines for the Evaluation and Treatment of Perimenopausal Depression

, 10 Claudio N. Soares, MD, PhD, MBA, 11 on behalf of the Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers Abstract There is a new appreciation of the perimenopause – defined as the early and late menopause transition stages as well as the early postmenopause - as a window of vulnerability for the development of both depressive symptoms and major depressive episodes. However, clinical (...) the National Pregnancy Registry for Atypical Antipsychotics, Alkermes Biopharmaceuticals, Forest/Actavis Pharmaceuticals, Otsuka Pharma- ceuticals, Sunovion Pharmaceuticals, Inc, Teva Pharmaceuticals, the Brain & Behavior Research Foundation, JayMac Pharmaceuticals, SAGE Therapeutics, and Takeda/Lundbeck Pharmaceuticals, as well as consul- tant fees from Alkermes Biopharmaceuticals. Dr. Soares has received honoraria as a consultant for Bayer, Lundbeck, Otsuka and Pfizer. He has also received grants from

2018 The North American Menopause Society

60. QTc Prolongation and Psychotropic Medications

about electrolyte monitoring will facilitate the process and minimize duplication. Acute medical conditions (e.g., gastroenteritis, endocrinopathies), physiological conditions (e.g., gravida emesis, strenuous exercise), or fasting can also cause electrolyte disruption. Furthermore, certain diagnoses can be accompanied by behaviors (e.g., purging and/or dietary restriction in eating disorders, binge drinking in alcohol use disorder, use of © Copyright, American Psychiatric Association, all rights (...) General Hospital, Boston, MA; 3 Harvard Medical School, Boston, MA; 4 Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI; 5 Mount Pearl, Newfoundland, Canada; 6 Department of Psychiatry, Virginia Commonwealth University, Richmond, VA; 7 Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL; 8 Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI; 9 Krannert Institute of Cardiology

2018 American Psychiatric Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>